Hazard rates of recurrence following diagnosis of primary breast cancer
- PMID: 15692760
- DOI: 10.1007/s10549-004-1722-0
Hazard rates of recurrence following diagnosis of primary breast cancer
Abstract
We calculated hazard rates for recurrence in patients with primary breast cancer (stage I, II; no adjuvant therapy). Previous publications have indicated a peak in hazard rates for recurrence (or death) at approximately 2-3 years after diagnosis of primary breast cancer. However, there have been conflicting reports concerning the presence of a second peak at 5-7 years after diagnosis. In this study, we estimated hazard functions by the Nelson-Aalen method and fit by cubic-linear and cubic-cubic-linear models to test for the presence of one or two peaks, respectively. We identified two peaks in hazard of recurrence, one at 2 years and another at 5 years. The 5-year peak, though statistically significant, represents very small differences in patient outcome. This additional peak may be an artifact of interval censoring due to a tendency to follow-up patients at specific bench-mark time points.
Comment in
-
Comment to Jatoi et al. report.Breast Cancer Res Treat. 2005 Sep;93(1):1-2. doi: 10.1007/s10549-005-3378-9. Breast Cancer Res Treat. 2005. PMID: 16184452 No abstract available.
Similar articles
-
[Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].Magy Onkol. 2007;51(2):127-31. Epub 2007 Jul 29. Magy Onkol. 2007. PMID: 17660868 Hungarian.
-
Selecting breast cancer patients with T1-T2 tumors and one to three positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy.Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1337-47. doi: 10.1016/j.ijrobp.2004.08.009. Int J Radiat Oncol Biol Phys. 2005. PMID: 15817335
-
Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer.Breast Cancer Res Treat. 2009 Sep;117(1):91-8. doi: 10.1007/s10549-008-0291-z. Epub 2008 Dec 27. Breast Cancer Res Treat. 2009. PMID: 19112615
-
Breast conservation surgery achieving>or=2 mm tumor-free margins results in decreased local-regional recurrence rates.Breast J. 2006 Jan-Feb;12(1):28-36. doi: 10.1111/j.1075-122X.2006.00181.x. Breast J. 2006. PMID: 16409584
-
259 Patients with DCIS of the breast applying USC/Van Nuys prognostic index: a retrospective review with long term follow up.Breast Cancer Res Treat. 2008 Jun;109(3):405-16. doi: 10.1007/s10549-007-9668-7. Epub 2007 Aug 9. Breast Cancer Res Treat. 2008. PMID: 17687650 Review.
Cited by
-
Intraoperative ketorolac in high-risk breast cancer patients. A prospective, randomized, placebo-controlled clinical trial.PLoS One. 2019 Dec 4;14(12):e0225748. doi: 10.1371/journal.pone.0225748. eCollection 2019. PLoS One. 2019. PMID: 31800611 Free PMC article. Clinical Trial.
-
Putative growth characteristics of micrometastatic breast cancer.Breast Cancer Res. 2008;10(6):114. doi: 10.1186/bcr2197. Epub 2008 Nov 27. Breast Cancer Res. 2008. PMID: 19090969 Free PMC article.
-
Recurrence dynamics does not depend on the recurrence site.Breast Cancer Res. 2008;10(5):R83. doi: 10.1186/bcr2152. Epub 2008 Oct 9. Breast Cancer Res. 2008. PMID: 18844974 Free PMC article.
-
Breast and colorectal cancer recurrence and progression captured by five U.S. population-based registries: Findings from National Program of Cancer Registries patient-centered outcome research.Cancer Epidemiol. 2020 Feb;64:101653. doi: 10.1016/j.canep.2019.101653. Epub 2020 Jan 6. Cancer Epidemiol. 2020. PMID: 31918179 Free PMC article.
-
Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897. Breast Cancer Res. 2011. PMID: 21663668 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical